07:41 AM EDT, 07/01/2024 (MT Newswires) -- AstraZeneca ( AZN ) said in a Monday filing that the European Medicines Agency's Committee for Medicinal Products for Human Use, or CHMP, has recommended approval for the combination of Lynparza and Imfinzi as a treatment for certain patients with primary advanced or recurrent endometrial cancer.

The company said Lynparza and Imfinzi have been recommended for patients with mismatch repair proficient, or pMMR, disease, to follow Imfinzi plus chemotherapy as the first-line treatment. The recommendation was based on a trial that demonstrated a 43% reduction in the risk of disease progression or death for pMMR patients treated with the combination therapy, according to the statement.

AstraZeneca ( AZN ) said Imfinzi was also recommended as a treatment for patients with mismatch repair deficient, or dMMR disease, to follow Imfinzi plus chemotherapy as the first-line treatment.

Price: 78.14, Change: +0.15, Percent Change: +0.19